UK antitrust watchdog's latest drug-pricing setback leaves plenty to chew on
A court setback for the UK competition regulator this week in its long-running case against Pfizer and Flynn Pharma over drug pricing is a lesson that how it goes about finding...To view the full article, register now.
Already a subscriber? Click here to view full article